Fonar Header
 
Fonar Press Releases

For Immediate Release

The Inventor of MR Scanning™

An ISO 9001 Company

Contact: Daniel Culver

110 Marcus Drive

Director of Communications

Melville, NY 11747-4292

Web site: www.fonar.com

Phone: (631) 694-2929

Email: investor @ fonar. com

Fax: (631) 390-1709

FONAR ANNOUNCES FISCAL 2020 3RD QUARTER AND NINE MONTHS FINANCIAL RESULTS; COMPANY BALANCE SHEET REMAINS STRONG AMID COVID-19 CRISIS

  • COVID-19 drastically affects imaging center scan volumes and delays installations of two MRI scanners until 1st Quarter of Fiscal 2021. Upon their completion, FONAR subsidiary, HMCA, will have 38 MRI scanners under its management

  • Cash and Cash Equivalents were $31.0 million as of March 31, 2020.

  • Total Revenues-Net decreased 5% to $21.7million for the quarter ended March31, 2020, versus corresponding quarter one year earlier.

  • Income from Operations was $2.6 million for the quarter ended March 31, 2020.

  • Net Income was$1.9 million for the quarter ended March 31, 2020.

  • Diluted Net Income per Common Share Available to Common Stockholders was $0.18 for the quarter ended March 31, 2020.

  • Total Current Assets were $91.4 million and Total Current Liabilities were $14.9 million at March 31, 2020.

  • Total Assets were $171.2 million and Total Liabilities were $45.6 million at March 31, 2020.

MELVILLE, NEW YORK, May 11, 2020 - FONAR Corporation (NASDAQ-FONR), The Inventor of MR Scanning™, reported today its financial results for the Fiscal 2020 3rd Quarter and Nine Months period ended March 31, 2020. FONAR’s primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). In 2009, HMCA managed 9 MRI scanning centers; it currently manages 25 MRI scanning centers. The impact the COVID-19 crisis had on the Company during the 3rd Quarter is discussed under Significant Event and Management Discussion below.

Operating Results

Total Revenues-Net decreased 5% for the third fiscal quarter ended March 31, 2020 to $21.7 million as compared to $22.8 million for the corresponding quarter one year earlier. Total Revenues-Net for the nine-month period ended March 31, 2020 were $64.9 million as compared to $64.7 million for the corresponding nine-month period one year earlier.

Income from Operations, for the third fiscal quarter ended March 31, 2020,was $2.6 million, as compared to $6.6 million for the corresponding quarter one year earlier. Income from Operations, for the nine-month period ended March 31, 2020, was $13.1million, as compared to $18.1 million for the corresponding nine-month period one year earlier.

Net Income,for the third fiscal quarter ended March 31, 2020, was $1.9 million as compared to $5.2 million for the corresponding quarter one year earlier. Net Income, for the nine-month period ended March 31, 2020, was $10.6 million, as compared to $14.6 million for the corresponding nine-month period one year earlier.

Diluted Net Income Per Common Share Available to Common Shareholders, for the third fiscal quarter ended March 31, 2020, was $0.18 as compared to $0.56 for the corresponding quarter one year earlier. Diluted Net Income Per Common Share Available to Common Shareholders,for the nine-month period ended March 31, 2020,was $1.10, as compared to $1.55 for the corresponding nine-month period one year earlier.

Total Costs and Expenses, for the third fiscal quarter ended March 31, 2020, was $19.1 million as compared to $16.2 million for the corresponding quarter one year earlier. Total Costs and Expenses, for the nine-month period ended March 31, 2020, was $51.8 million, as compared to $46.6 million for the corresponding nine-month period one year earlier.

Balance Sheet Items

Total Cash and Cash Equivalents and Short Term Investments at March 31, 2020 increased 7% to $31.1million, versus $29.0million at June 30, 2019. This compared positively to$30.7 million for the prior fiscal quarter at December 31, 2019.

A recent accounting pronouncement, Accounting Standards Update (ASU)2016-02, required a Right to Use Asset of $29.1 million, and a Lease liability of $31.1 million,to be recorded during the third fiscal quarter of 2020, representing the present value of future lease payments, less year-end deferred rent balances and any tenant improvements committed to by landlords. There are no comparable assets or liabilities recorded for prior periods. Details of ASU 2016-02 may be found in the Company’s 10-K for the year ended June 30, 2019.

Total Current Assets,at March 31, 2020, were $91.4 million, as compared to $85.1 million,at June 30,2019.

Total Current Liabilities,at March 31, 2020 was$14.9 million, as compared to $14.1 million at June 30, 2019. Total Current Liabilities is impacted by the recent accounting pronouncement, specifically of the Lease liability –current portion of $3.2 million.

Total Assets, at March 31, 2020, were $171.2 million, as compared to $133.6 million at June 30, 2019. This includes the Right-of-use Assets-net of $29.1 million included in Fiscal 2020 but not included in Fiscal 2019.

Total Liabilities at March 31, 2020 were $45.6 million, as compared to $15.4 million at June 30, 2019. This includes Lease liability – net of current portion at $27.9 million and Lease liability – current portion at $3.2 million included in fiscal 2020. Lease liability – net of current portion and Lease liability – current portion were not included in fiscal 2019.

The Total Assets / Total Liabilities ratio for the quarter ended March 31, 2020, was 3.8 compared to 8.6 as of June 30, 2019. This difference is predominantly due to the effect of the recently adopted accounting pronouncement, ASU 2016-02, which required $29.1 million of assets and $31.1 million of liabilities to be recorded at March 31, 2020.

Significant Event

The COVID-19 pandemic reached our shores in March, 2020, in FONAR’s 3rd Quarter of Fiscal 2020, killing thousands, tumbling financial markets, and wreaking economic and social havoc across the country.  On March 9, 2020, the Dow Jones Industrial Average ($DJI) dropped 1080 points, 3.8% of its value. By March 23, 2020 it hit a low of 18,213 points, a drop of over 10,000 points from where it was a little over a month earlier.

Governmental “shut-down” directives requiring the closing of all nonessential businesses quickly followed. With doctors’ offices and healthcare providers deemed essential businesses, HMCA-managed sites, all of them located in New York and Florida, have been allowed to continue to serve patients in need of outpatient medical care. The FONAR MRI Scanner Service Department is also considered essential. 

As a result of the pandemic, scheduled elective patient care, including surgeries, has been cancelled or postponed.  Further, patients simply wary of contracting the coronavirus are cancelling, postponing or missing their doctor appointments.  The unavoidable sight of closed nonessential businesses and the constant urging or demand for all to maintain social distancing or to shelter in place have heightened patient fear and concern. Consequently, patient volume at medical offices, the source of MRI referrals, has dropped precipitously. In turn, so has scan volume at all HMCA-managed sites: 21% less than projected, pre-COVID-19, for March and 56% less than projected for April, pre-COVID-19. It appears that scan volume for May will be less than projected as well.

However, with the state of Florida now is the process of “reopening” and with the state of New York expected to follow suit in the near future, the Company expects scan volume at all HMCA-managed sites to begin to rise steadily in the 1st Quarter of Fiscal 2021.

Management Discussion

Timothy R. Damadian, President and CEO, said, “Prior to the COVID-19 pandemic disruption, we planned to invest between $4 million and $6 million dollars at four (4) scanning centers in Fiscal 2020.  In October, 2019, we installed a second MRI scanner in the facility we manage in Ormond Beach, Florida facility, and we expect to be installing by the end of June the first MRI in what will be a two-MRI facility in Pembroke Pines, Florida.  Unfortunately, the COVID-19 disruption has slowed down installations of second MRIs in two of the New York facilities we manage – one in Westchester County and the other in Suffolk County.  Nevertheless, I am pleased that these two installations are now expected to be completed during the first quarter of Fiscal 2021. When all 3 are installed, we will have a total of 39 MRI under our management. 

“The COVID-19 pandemic arrived in late March.  For the safety of employees and patients, we immediately implemented sanitary procedures at FONAR headquarters and at all HMCA-managed sites and ordered additional Personal Protective Equipment (PPE) needed for protection from the virus. Where possible, headquarter employees are now working from their homes.  Others, due to reduced workloads or restrictions that prevent them from doing their jobs as usual, have had their hours cut or have been furloughed.

“Once the states of Florida and New York are “reopened,” the COVID-19 pandemic under control, and patients back to seeing their physicians, we are confident we will be once again thriving and growing. At this point in time, no one can predict when that will happen, but I eagerly look forward to seeing the end of the pandemic, our employees and their families healthy and safe, our furloughed employees returned to work, and office hours and patient volume at the sites back to where they were in March.” 

Mr. Damadian concluded, “We have a very strong balance sheet.  With Cash and Cash Equivalents at $31.0 million and relatively little debt, the Company’s liquidity puts us in excellent position to weather the storm and continue to grow for the foreseeable future.”  

Chairman of the Board, Raymond V. Damadian, M.D., said, “It’s pleasing to see the Company continue to be profitable. My son, Timothy, and his highly experienced and competent management team, are doing an outstanding job. Since they took the reins in 2010, Total Revenues-Net has grown from $31.8 million to $87.2 million, representing an effective annual growth rate of nearly 12%.  The total MRI scan volume at HMCA-managed facilities in calendar year 2009 was 29,000 and 189,000 in calendar 2019.

“The importance of the FONAR UPRIGHT® Multi-Position™ MRI to the success of HMCA cannot be overstated,” continued Dr. Damadian. “Physicians are seeing how the diagnostic information obtained from having their patients scanned in weight-bearing positions, such as sitting, bending or standing, can lead to treatment plans that result in better patient outcomes. Scanning patients in these positions is possible only on the patent-protected UPRIGHT® Multi-Position™ MRI. It is well known that the majority of MRI studies are of the spine, and it is widely reported that about 80% of adults experience low back pain at some point in their lifetimes. This explains why the UPRIGHT® MRI has gained traction in the medical community.”

“Additionally, a significant portion of the patient population seeks to avoid their MRI exams in a claustrophobia-inducing “tunnel” or “tube” MRI, which is typical of most other MRIs. Most Upright® MRI patients are delighted to have their MRI scan while sitting and watching a wide-screen TV. This has been a highly-prized feature unique to FONAR and is supported by numerous patents that protect our technology from the large MRI competitors in the MRI industry.  Perhaps a silver lining in the "COVID -19 black cloud", is the relative ease with which Fonar UPRIGHT® scanner surfaces, in close proximity to patients, can be much  more easily sanitized and maintained than the "tunnel" or "tube" MRI scanners, with minimal exposure to staff and patients. We expect to continue to enjoy this competitive advantage well into the future.” 

Dr. Damadian continued, “Unfortunately, COVID-19 has delayed our R&D progress on MRI imaging of cerebrospinal fluid (CSF) flow and its impact on cerebral degenerative diseases. Our research is focused on quantifying CSF flow and the velocity at which it navigates through the neck and head. We’ve been able to use quantitative CSF data collected from asymptomatic patients to identify the degree to which CSF flow impairment is responsible for the patient’s symptoms and the degree to which the patient’s surgical or non-surgical CCJ treatment has restored the patient’s critical brain and central nervous symptom’s physiology to normal. We use the UPRIGHT® MRI to make cines (movies) of the fluid (CSF) as it flows up and down the neck and around the brain. We are also hopeful that our research may lead to a new understanding of the role of CSF on neurologic diseases, such as MS and Parkinson’s disease.

Dr. Damadian concluded, “Once the COVID-19 crisis is over and the economy returns to normal, there is every reason to believe that FONAR will continue to prosper.”

About FONAR

FONAR, the Inventor of MR Scanning™, is located in Melville, NY, was incorporated in 1978, and is the first, oldest and most experienced MRI company in the industry. FONAR introduced the world’s first commercial MRI in 1980, and went public in 1981. FONAR’s signature product is the FONAR UPRIGHT® Multi-Position™ MRI (also known as the Stand-Up® MRI), the only whole-body MRI that performs Position™ Imaging (pMRI™) and scans patients in numerous weight-bearing positions, i.e. standing, sitting, in flexion and extension, as well as the conventional lie-down position. The FONAR UPRIGHT® MRI often detects patient problems that other MRI scanners cannot because they are lie-down and ”weightless” only scanners. The patient-friendly UPRIGHT® MRI has a near-zero patient claustrophobic rejection rate. As a FONAR customer states, “If the patient is claustrophobic in this scanner, they’ll be claustrophobic in my parking lot.” Approximately 85% of patients are scanned sitting while watching TV.

FONAR has new works-in-progress technology for visualizing and quantifying the cerebral hydraulics of the central nervous system, the flow of cerebrospinal fluid (CSF), which circulates throughout the brain and vertebral column at the rate of 32 quarts per day. This imaging and quantifying of the dynamics of this vital life-sustaining physiology of the body’s neurologic system has been made possible first by FONAR’s introduction of the MRI and now by this latest works-in-progress method for quantifying CSF in all the normal positions of the body, particularly in its upright flow against gravity. Patients with whiplash or other neck injuries are among those who will benefit from this new understanding.

FONAR’s substantial list of patents includes recent patents for its technology enabling full weight-bearing MRI imaging of all the gravity sensitive regions of the human anatomy, especially the brain, extremities and spine. It includes its newest technology for measuring the Upright cerebral hydraulics of the central nervous system. FONAR’s UPRIGHT® Multi-Position™ MRI is the only scanner licensed under these patents.

UPRIGHT® and STAND-UP® are registered trademarks and The Inventor of MR Scanning™, Full Range of Motion™, Multi-Position™, Upright Radiology™, The Proof is in the Picture™, True Flow™, pMRI™, Spondylography™, Dynamic™, Spondylometry™, CSP™, and Landscape™, are trademarks of FONAR Corporation.

This release may include forward-looking statements from the company that may or may not materialize. Additional information on factors that could potentially affect the company's financial results may be found in the company's filings with the Securities and Exchange Commission.

 

FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)

ASSETS

 
March 31,
2020
June 30,
2019 *
Current Assets:    
Cash and cash equivalents      
$ 31,019
$ 13,882
Short term investments
32
15,095
Accounts receivable – net
3,832
3,737
Accounts receivable - related party

30

 

Medical receivable – net
16,481
15,729
Management and other fees receivable - net
28,007

25,709

 

Management and other fees receivable – related medical practices – net
7,035
6,501
Inventories
1,775
1,798
Costs and estimated earnings in excess of billings on uncompleted contracts
153

525

 

Income tax receivable
1,200
600
Prepaid expenses and other current assets
1,798
1,513
Total Current Assets
91,362
85,089
     
Accounts receivable – net
2,166
Income taxes receivable
600
Deferred income tax asset
18,457
20,937
Property and equipment – net
21,258
16,986
Right-of-use assets – net
29,145
Goodwill
3,985
3,985
Other Intangible Assets – net
4,162
4,756
Other Assets
645
1,207
Total Assets
$ 171,180
$ 133,560

CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)

LIABILITIES AND STOCKHOLDERS’ EQUITY

 
March 31,
2020
June 30,
2019 *

Current Liabilities:

Current portion of long-term debt and capital leases
$ 34
$ 41
Accounts payable
1,687

1,861

 

Other current liabilities
5,162
7,577
Unearned revenue on service contracts
3,912
3,812
Unearned revenue on service contracts - related party
27
Lease liability – current portion
3,214
Customer deposits
854
799

Total Current Liabilities

14,890
14,090
     

Long-Term Liabilities:

Unearned revenue on service contracts
2,096
Deferred income tax liability
243
243
Due to related medical practices
93
93
Long-term debt and capital leases, less current portion
247
273
Lease liability - net of current portion
27,885
Other liabilities
139
749
     
Total Long-Term Liabilities
30,703
1,358
Total Liabilities
45,593
15,448

CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)
  
LIABILITIES AND STOCKHOLDERS’ EQUITY (Continued)

 
March 31,
2020
June 30,
2019 *

STOCKHOLDERS' EQUITY:

Class A non-voting preferred stock $.0001 par value; 453 shares authorized at March 31, 2020 and June 30, 2019, 313 issued and outstanding at March 31, 2020 and June 30, 2019
$ —
$ —
Preferred stock $.001 par value; 567 shares authorized at March 31, 2020 and June 30, 2019, issued and outstanding – none
Common Stock $.0001 par value; 8,500 shares authorized at March 31, 2020 and June 30, 2019, 6,459 and 6,369 issued at March 31, 2020 and June 30, 2019, 6,447 and 6,357 outstanding at March 31, 2020 and June 30, 2019
1
1
Class B Common Stock (10 votes per share) $.0001 par value; 227 shares authorized at March 31, 2020 and June 30, 2019; .146 issued and outstanding at March 31, 2020 and June 30, 2019
Class C Common Stock (25 votes per share) $.0001 par value; 567 shares authorized at March 31, 2020 and June 30, 2019, 383 issued and outstanding at March 31, 2020 and June 30, 2019
Paid-in capital in excess of par value
183,076
181,086
Accumulated deficit

(56,792

)

(64,456)
Treasury stock, at cost - 12 shares of common stock at March 31, 2020 and June 30, 2019
(675 )
(675 )
Total Fonar Corporation’s Stockholders’ Equity
125,610
115,956
Noncontrolling interests
(23)
2,156
Total Stockholders' Equity
125,587
118,112
Total Liabilities and Stockholders' Equity
$ 171,180
================
$ 133,560
================


CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)

 
FOR THE THREE MONTHS ENDED MARCH 31,
 
2020
2019

REVENUES

Patient fee revenue – net of contractual allowances and discounts
$ 5,713
$ 6,410
Product sales – net
92
796
Service and repair fees – net
1,942
1,964
Service and repair fees - related parties – net
28
28
Management and other fees – net
11,218
11,191
Management and other fees - related medical practices – net
2,693
2,390
Total Revenues – Net
21,686
22,779

COSTS AND EXPENSES

Costs related to patient fee revenue
2,840
2,740
Costs related to product sales
235
216
Costs related to service and repair fees
674
752
Costs related to service and repair fees - related parties
9
10
Costs related to management and other fees
6,004
5,834
Costs related to management and other fees – related medical practices
1,550
1,634
Research and development
535
381
Selling, general and administrative
7,224
4,604
Total Costs and Expenses
19,071
16,171
Income from Operations
2,615
6,608
Interest Expense
(17)
(27)
Investment Income
126
104
Income Before Provision for Income Taxes and Noncontrolling Interests
2,724
6,685
Provision for Income Taxes
(810)
(1,484
Net Income
1,914
5,201
Net Income - Noncontrolling Interests
(653)
(1,338)
Net Income - Controlling Interests
1,261
================
3,863
================
Net Income Available to Common Stockholders
1,184
================
3,623
================
Net Income Available to Class A Non-Voting Preferred Stockholders
57
================
179
================
Net Income Available to Class C Common Stockholders
20
================
61
================
Basic Net Income Per Common Share Available to Common Stockholders
0.18
================
0.57
================
Diluted Net Income Per Common Share Available to Common Stockholders
0.18
================
0.56
================
Basic and Diluted Income Per Share – Class C Common
$ 0.05
================
$ 0.16
================
Weighted Average Basic Shares Outstanding – Common Stockholders
6,447
================
6,357
================
Weighted Average Diluted Shares Outstanding - Common Stockholders
6,575
================
6,485
================
Weighted Average Basic Shares Outstanding – Class C Common
383
================
383
================
Weighted Average Diluted Shares Outstanding – Class C Common
383
================
383
================

CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Amounts and shares in thousands, except per share amounts)
(UNAUDITED)

 
FOR THE NINE MONTHS
ENDED MARCH 31,
 
2020
2019

REVENUES

Patient fee revenue – net of contractual allowances and discounts
$ 17,754
$ 17,856
Product sales – net
288
1,241
Service and repair fees – net
6,044
6,116
Service and repair fees - related parties – net
83
83
Management and other fees – net
33,242
32,448
Management and other fees - related medical practices – net
7,473
6,965
Total Revenues – Net
64,884
64,709

COSTS AND EXPENSES

Costs related to patient fee revenue
8,660
8,016
Costs related to product sales
685
539
Costs related to service and repair fees
2,196
2,242
Costs related to service and repair fees – related parties
30
30
Costs related to management and other fees
18,203
17,493
Costs related to management and other fees – related medical practices
4,707
4,421
Research and development
1,590
1,368
Selling, general and administrative
15,691
12,474
Total Costs and Expenses
51,762
46,583
Income from Operations
13,122
18,126
Interest Expense
(57)
(78)
Investment Income
413
336
Other Income
1
Income Before Provision for Income Taxes and Noncontrolling Interests
13,479
18,384
Provision for Income Taxes
(2,849)
(3,826)
Net Income
10,630
14,558
Net Income - Noncontrolling Interests
(2,966)
(3,824)
Net Income - Controlling Interests
$ 7,664
================
$ 10,734
================
Net Income Available to Common Stockholders
$ 7,194
================
$ 10,067
================
Net Income Available to Class A Non-Voting Preferred Stockholders
$ 350
================
$ 496
================
Net Income Available to Class C Common Stockholders
$ 120
================
$ 170
================
Basic Net Income Per Common Share Available to Common Stockholders
$ 1.12
================
$ 1.58
================
Diluted Net Income Per Common Share Available to Common Stockholders
$ 1.10
================
$ 1.55
================
Basic and Diluted Income Per Share – Class C Common
$ 0.31
================
$0.44
================
Weighted Average Basic Shares Outstanding – Common Stockholders
$ 6,442
================
$ 6,353
================
Weighted Average Diluted Shares Outstanding – Common Stockholders
$ 6,570
================
$ 6,481
================
Weighted Average Basic Shares Outstanding – Class C Common
$ 383
================
$ 383
================
Weighted Average Diluted Shares Outstanding – Class C Common
$ 383
================
$ 383
================

FONAR™ Corporation
110 Marcus Drive
Melville, N.Y. 11747
Tel. 631-694-2929
Fax. 631-390-9540
Email sales@FONAR.com
Investor Information

top of page

Site Map | Terms of Use-Our Privacy Policy Use
Copyright 2020 FONAR- All Rights Reserved